drugset / Trial / NCT00563056

An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma

NCT00563056

Phase 3 Completed 227 enrolled Mundipharma Research Limited
RandomizedParallel-groupOpen-labelTreatment

Summary

Flutiform® compared with the individual components Flixotide® (Fluticasone) and Foradil® (Formoterol) in adolescent and adult patients.

Timeline

Start
2007-09
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluticasone Other / unclassified 100 ug Inhaled
Comparator Fluticasone Other / unclassified 250 ug Inhaled
Comparator Formoterol Other / unclassified 12 ug Inhaled
Subject fluticasone/formoterol Unknown Inhaled

Indications